ALX Oncology Holdings Inc. announced it has entered into a clinical trial collaboration and supply agreement with Sanofi to evaluate the combination of evorpacept, a CD47 blocker, and SARCLISA, Sanofi’s monoclonal antibody that targets a specific epitope on the CD38 receptor on multiple myeloma cells, for the treatment of patients with relapsed or refractory multiple myeloma.
[ALX Oncology Holdings, Inc.]
